D ue to the increasing burden of non-communicable diseases (NCDs) in aging populations and the prevalence of unhealthy lifestyles, end-stage renal disease (ESRD) that results from NCDs is a growing concern in Indonesia. With the target of achieving Universal Health Coverage (UHC) by 2019, public provision of treatment to address the burden of ESRD will become financially unsustainable due to the high cost of dialysis – unless an appropriate policy is developed. Treatments for ESRD currently included in the benefit package under the National Health Insurance Scheme called the Jaminan Kasehatan Nasional (JKN) are for both hemodialyses (HD) and peritoneal dialysis (PD). Both modalities offer substantial health benefits over supportive care albeit at a very high cost. Despite this, peritoneal dialysis as the first line treatment (PD-first policy) for ESRD patients is recommended to be implemented under the JKN as it is less costly but provides a similar level of health benefit compared to that of hemodialysis.